Morgan Stanley
BHVN

Morgan Stanley’s Biohaven Pharmaceutical Holding Company Ltd. BHVN Stock Holding History

Morgan Stanley’s Portfolio BHVN Stock Details BHVN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-565,941
Closed -$85.6M – 8204
2022
Q3 		$85.6M Buy
565,941
+375,508
+197% +$55.7M 0.01% 985
2022
Q2 		$27.7M Buy
190,433
+87,881
+86% +$11.2M ﹤0.01% 1928
2022
Q1 		$12.2M Buy
102,552
+19,949
+24% +$2.49M ﹤0.01% 2679
2021
Q4 		$11.4M Buy
82,603
+40,245
+95% +$5.12M ﹤0.01% 2808
2021
Q3 		$5.88M Sell
42,358
-11,311
-21% -$1.41M ﹤0.01% 3503
2021
Q2 		$5.21M Buy
53,669
+12,560
+31% +$1.02M ﹤0.01% 3738
2021
Q1 		$2.81M Sell
41,109
-100,556
-71% -$8.13M ﹤0.01% 3987
2020
Q4 		$12.1M Buy
141,665
+91,018
+180% +$7.71M ﹤0.01% 2302
2020
Q3 		$3.29M Sell
50,647
-30,819
-38% -$2.02M ﹤0.01% 3148
2020
Q2 		$5.96M Buy
81,466
+24,410
+43% +$1.3M ﹤0.01% 2485
2020
Q1 		$1.94M Sell
57,056
-18,605
-25% -$851K ﹤0.01% 3396
2019
Q4 		$4.12M Buy
75,661
+681
+0.9% +$33.7K ﹤0.01% 3408
2019
Q3 		$3.13M Sell
74,980
-18,882
-20% -$798K ﹤0.01% 3372
2019
Q2 		$4.11M Buy
93,862
+14,539
+18% +$820K ﹤0.01% 3115
2019
Q1 		$4.08M Buy
79,323
+32,617
+70% +$1.41M ﹤0.01% 2900
2018
Q4 		$1.73M Sell
46,706
-55,648
-54% -$2.01M ﹤0.01% 3885
2018
Q3 		$3.84M Sell
102,354
-141,996
-58% -$5.22M ﹤0.01% 3461
2018
Q2 		$9.66M Buy
244,350
+164,054
+204% +$5.21M ﹤0.01% 2412
2018
Q1 		$2.07M Buy
80,296
+49,179
+158% +$1.47M ﹤0.01% 3983
2017
Q4 		$839K Buy
31,117
+4,173
+15% +$115K ﹤0.01% 4666
2017
Q3 		$1.01M Buy
26,944
+15,382
+133% +$467K ﹤0.01% 4424
2017
Q2 		$289K Buy
+11,562
New +$266K ﹤0.01% 5131

Other funds holding BHVN

LIP
Liontrust Investment Partners London, United Kingdom $5.86B AUM 23.75% 1-Year Est. Return
KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
BC
Birchview Capital Burlington, Vermont $176M AUM 95.04% 1-Year Est. Return
BTI
Blue Trust Inc Alpharetta, Georgia $8.74B AUM 14.62% 1-Year Est. Return
FIA
FNY Investment Advisers New York $278M AUM 98.95% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $4.82B AUM 20.19% 1-Year Est. Return
MSCM
McElhenny Sheffield Capital Management Dallas, Texas $403M AUM 28.73% 1-Year Est. Return

Morgan Stanley's BHVN Position: Q4 2022 in Review

Morgan Stanley sold out of Biohaven Pharmaceutical Holding Company Ltd. (BHVN) in Q4 2022, closing a stake of 565,941 shares — an estimated $85.6M sold.

Morgan Stanley first reported a position in BHVN in Q2 2017 and held it in 22 quarters. The position peaked at $85.6M in Q3 2022. 7 funds tracked by Wall St. Rank hold BHVN as of Q4 2022.

  • Morgan Stanley reported no remaining Biohaven Pharmaceutical Holding Company Ltd. position as of Q4 2022 after selling out during the quarter.
  • Morgan Stanley sold 565,941 Biohaven Pharmaceutical Holding Company Ltd. shares in Q4 2022, an estimated $85.6M.
  • Morgan Stanley first reported a position in Biohaven Pharmaceutical Holding Company Ltd. in Q2 2017 and held it in 22 quarters.
  • Morgan Stanley's Biohaven Pharmaceutical Holding Company Ltd. position peaked at $85.6M in Q3 2022.
  • 7 funds tracked by Wall St. Rank held Biohaven Pharmaceutical Holding Company Ltd. as of Q4 2022.

Based on Morgan Stanley's 13F filing for Q4 2022, filed 14 Feb 2023.